TY - JOUR
T1 - Methodological and reporting quality of breast cancer screening guidelines: A systematic review
AU - Li, Jiang
AU - Tang, Wei
AU - Li, Ni
AU - Wang, Xin
AU - Wang, Yong
AU - Lv, Zhangyan
AU - Feng, Xiaoshuang
AU - Wei, Luopei
AU - Li, Xin
AU - Sun, Xin
AU - Chen, Wanqing
AU - Dai, Min
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-21
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Objectives To systematically review the methodological and reporting quality of the current global breast cancer screening guidelines so as to provide useful information for domestic study in the future. Methods We searched databases including PubMed, The Cochrane Library, Web of Science, EMbase, CNKI, CBM, WanFang Data and some cancer official websites to collect breast cancer screening guidelines from inception to February, 2018. Two reviewers independently screened literature, extracted data and assessed the quality of the guidelines by using AGREE II tool and RIGHT statement. Results A total of 11 guidelines were included, in which 5 guidelines (45%) were issued by the USA. The results of the quality assessment showed that: the average scores in the “scale and objective”, “participants”, “rigorism”, “clarity”, “application”, and “independence” of all guidelines were 83, 48, 60, 77, 53 and 79, respectively. 6 guidelines were evaluated as level A and 5 as level B. For the reporting quality, 3 guidelines were of high quality, including 2 in the USA and 1 in Canada. Conclusions The methodological and reporting quality of breast cancer screening guidelines are at present very satisfactory. The quantity of clinical guidelines shows an increasing trend. Multi-country contribution to one guideline is another trend. The evidence-based methodology has been accepted globally in the guideline development.
AB - Objectives To systematically review the methodological and reporting quality of the current global breast cancer screening guidelines so as to provide useful information for domestic study in the future. Methods We searched databases including PubMed, The Cochrane Library, Web of Science, EMbase, CNKI, CBM, WanFang Data and some cancer official websites to collect breast cancer screening guidelines from inception to February, 2018. Two reviewers independently screened literature, extracted data and assessed the quality of the guidelines by using AGREE II tool and RIGHT statement. Results A total of 11 guidelines were included, in which 5 guidelines (45%) were issued by the USA. The results of the quality assessment showed that: the average scores in the “scale and objective”, “participants”, “rigorism”, “clarity”, “application”, and “independence” of all guidelines were 83, 48, 60, 77, 53 and 79, respectively. 6 guidelines were evaluated as level A and 5 as level B. For the reporting quality, 3 guidelines were of high quality, including 2 in the USA and 1 in Canada. Conclusions The methodological and reporting quality of breast cancer screening guidelines are at present very satisfactory. The quantity of clinical guidelines shows an increasing trend. Multi-country contribution to one guideline is another trend. The evidence-based methodology has been accepted globally in the guideline development.
UR - http://www.cjebm.com/article/10.7507/1672-2531.201803081
UR - http://www.scopus.com/inward/record.url?scp=85050759291&partnerID=8YFLogxK
U2 - 10.7507/1672-2531.201803081
DO - 10.7507/1672-2531.201803081
M3 - Article
SN - 1672-2531
VL - 18
SP - 629
EP - 639
JO - Chinese Journal of Evidence-Based Medicine
JF - Chinese Journal of Evidence-Based Medicine
IS - 6
ER -